Lenvatinib (E7080) , ≥99% , 417716-92-8

CAS NO.：417716-92-8

Empirical Formula: C21H19ClN4O4

Molecular Weight: 426.85

MDL number: MFCD16038644

EINECS: 1592732-453-0

PRODUCT Properties

• Melting point: >216°C (dec.)
• Boiling point: 627.2±55.0 °C(Predicted)
• Density: 1.46
• storage temp.: -20°C
• solubility: Soluble in DMSO (up to 20 mg/ml)
• pka: 13.09±0.70(Predicted)
• form: solid
• color: White
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.

Description and Uses

Lenvatinib is an inhibitor of the receptor tyrosine kinases VEGF receptor 2 (VEGFR2) and VEGFR3 (IC₅₀s = 4 and 5.2 nM, respectively). It also inhibits the related kinases VEGFR1, FGFR1, PDGFRα, PDGFRβ and Kit (IC₅₀s = 22, 46, 51, 39, and 100 nM, respectively). Lenvatinib (30 mg/kg, twice per day) reduces tumor growth in an H146 small cell lung cancer mouse xenograft model and induces tumor regression when administered at a dose of 100 mg/kg twice per day. Formulations containing lenvatinib have been used in the treatment of differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.

Lenvatinib is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors.